Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib and Chemoembolization in Unresectable Hepatocellular Cancer
NCT00524316Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in hepatocellular carcinoma (HCC), sponsored by Roswell Park Comprehensive Cancer Center. Started Apr 2007; status: terminated.
02
Drugs
sunitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00524316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00524316.